Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADNP antisense RNA 1 (ADNP-AS1) is an annotated long non-coding RNA (lncRNA) that is transcribed starting from exon 1 of the ADNP gene but in the opposite (antisense) direction[3]. As a non-coding transcript, it does not encode a protein. The functional significance of ADNP-AS1 remains unclear, and it is not known whether it possesses true antisense activity that regulates the expression of the ADNP gene or other cellular processes[3]. There is no direct evidence linking ADNP-AS1 to drug interactions, established molecular pathways, disease mechanisms, or utility as a biomarker at this time. Its presence is primarily noted in genomic annotation, and further research is needed to elucidate its exact biological functions and clinical relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADNP antisense RNA 1 (ADNP-AS1).